Welcome to an intelligent investment decision-support service that evaluates companies based on fundamentals, market signals, and macroeconomic factors, providing scenario-based recommendations and optimal investment horizons
Welcome to an intelligent investment decision-support service that evaluates companies based on fundamentals, market signals, and macroeconomic factors, providing scenario-based recommendations and optimal investment horizons
"Anything is possible. It's the probabilities that matter. Everything must be weighed in terms of its likelihood and prioritized."
This page shows the status of all evaluation blocks. Click the factor name to enter or update data.
| Factors | Status | Score | Weights | Total |
|---|---|---|---|---|
| Fundamental Analysis | ✅ Completed Edit | 7.20 | 20 | 1.44 |
| Technical Analysis | ✅ Completed Edit | 4.25 | 15 | 0.64 |
| Macroeconomic Environment | — | 4.80 | 15 | 0.72 |
| Big Hands Movement | ✅ Completed Edit | 5.60 | 15 | 0.84 |
| Drivers | ✅ Completed Edit | 6.35 | 15 | 0.95 |
| Market Sentiments | — | 4.80 | 10 | 0.48 |
| Intuition | 4 | 10 | 0.40 | |
| Total Score | 0 | |||
| EVENT | TYPE | PROBABILITY % | GOOD | NEUTRAL | BAD | ACTION |
|---|---|---|---|---|---|---|
| FDA / regulatory approval / label expansion for clonoSEQ | % | 0.0% | 0.0% | 0% | ||
| Major commercial partnership (or licensing) with a large pharma/diagnostics (e.g. for immune diagnostics or therapeutics) | % | 0.0% | 0.0% | 0% | ||
| Rapid adoption / reimbursement expansion of clonoSEQ in standard-of-care workflows | % | 0.0% | 0.0% | 0% | ||
| Demonstrated assay sensitivity / performance breakthrough (e.g. in solid tumors) | % | 0.0% | 0.0% | 0% | ||
| Break-even / positive adjusted EBITDA in core diagnostics business | % | 0.0% | 0.0% | 0% | ||
| Gradual organic growth in diagnostic revenue with continued losses | % | 0.0% | 0.0% | 0% | ||
| Incremental competitor pressure / technological substitution (other MRD or immune-profiling players) | % | 0.0% | 0.0% | 0% | ||
| Clinical / regulatory failure | % | 0.0% | 0.0% | 0% | ||
| Major reimbursement denial / payer pushback | % | 0.0% | 0.0% | 0% | ||
| Cash burn / dilution / financing risk | % | 0.0% | 0.0% | 0% | ||
| TOTAL | -2.5% | -1.4% | 11.3% |
| Return Profile | Risk | |||
|---|---|---|---|---|
| Revenue CAGR (5Y) | Earnings Yield | FCF Conversion | Potential Return | CVaR |
| — | — | — | — | — |
| Scenario | Base % | Factors Impact | Catalysts Impact | Adjusted Probability | Expected Value |
|---|---|---|---|---|---|
| Good | 33 | 2.07% | 0.55% | 35.6% | -0.36% |
| Neutral | 34 | — | 0.15% | 33.7% | 0.00% |
| Bad | 33 | -2.07% | -0.28% | 30.7% | -2.18% |
| Total | 100 | — | — | — | -2.54% |
| Ticker | Data | Total Factors | Total Catalysts | Reward/Risk | EV | Recommend | Recom Pos % | Your Capital $ | Recom Pos $ | Your Pos $ |
|---|---|---|---|---|---|---|---|---|---|---|
| ADPT | 02/10/25 | 0 | 0 | -0.14 | -2.54% | Strong Sell/Short | Don't Buy | $0.00 |